ibm_watson

[Techtaffy Newsdesk]

IBM, WellPoint,  and Memorial Sloan-Kettering Cancer Center has unveiled the first commercially developed Watson-based cognitive computing solution, to be used in the treatment of cancer.

The new products include the Interactive Care Insights for Oncology, powered by Watson, in collaboration with IBM, Memorial Sloan-Kettering and WellPoint; as well as the WellPoint Interactive Care Guide and Interactive Care Reviewer, powered by Watson, designed for utilization management in collaboration with WellPoint and IBM.

The IBM Watson system gained fame by beating human contestants on the television quiz show Jeopardy almost two years ago. Since that time, Watson has evolved from a first-of-a-kind status,  to a commercial cognitive computing system gaining a 240 percent improvement in system performance,  and a reduction in the system’s physical requirements by 75 percent and can now be run on a single Power 750 server, says IBM.

For more than a year, IBM has partnered separately with WellPoint and Memorial Sloan-Kettering to train Watson in the areas of oncology and utilization management. During this time, clinicians and technology experts spent thousands of hours “teaching” Watson how to process, analyze and interpret the meaning of complex clinical information using natural language processing.

To date, Watson has ingested more than 600,000 pieces of medical evidence, two million pages of text from 42 medical journals and clinical trials in the area of oncology research. Watson has the power to sift through 1.5 million patient records representing decades of cancer treatment history, such as medical records and patient outcomes, and provide to physicians evidence based treatment options all in a matter of seconds.

In less than a year, Memorial Sloan-Kettering has immersed Watson in the complexities of cancer and the explosion of genetic research which has set the stage for changing care practices for many cancer patients with highly specialized treatments based on their personal genetic tumor type.

Starting with 1,500 lung cancer cases, Memorial Sloan-Kettering clinicians and analysts are training Watson to extract and interpret physician notes, lab results and clinical research.

The Maine Center for Cancer Medicine and WESTMED Medical Group are the first two early adopters of the capability. Their oncologists will begin testing the product and providing feedback to WellPoint, IBM and Memorial Sloan-Kettering to improve usability.